IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Modern Diagnostic & Research Centre IPO is a Book Building listing on BSE SME exchange. The company is based in New Delhi and caters to Healthcare - Hospitals And Clinic sector. Beeline Capital Advisors is the merchant banker of Modern Diagnostic & Research Centre IPO. It is a SME Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 31st March 2025.
Modern Diagnostic & Research Centre IPO posted revenues of ₹ 80.66 crores and PAT of ₹ 9.92 crores in FY25 on annualised basis.
Revenue:
₹ 80.66 Cr.
EBITDA Margin:
23.95 % 
Net Worth: ₹ 16.71 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Financial results of Modern Diagnostic & Research Centre IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Modern Diagnostic & Research Centre IPO PAT Margin is 12.30 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Modern Diagnostic & Research Centre IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Modern Diagnostic & Research Centre IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Modern Diagnostic & Research Centre IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Modern Diagnostic & Research Centre IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Modern Diagnostic & Research Centre IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Modern Diagnostic & Research Centre IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Modern Diagnostic & Research Centre IPO reported revenue of ₹ 80.66 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Modern Diagnostic & Research Centre IPO provide insights into sales growth, market demand, and business scalability.
Modern Diagnostic & Research Centre recorded an EBITDA of ₹ 19.32 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Modern Diagnostic & Research Centre Profit After Tax (PAT) is ₹ 9.92 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 80.66 Cr.
EBITDA Margin:
23.95
%
Net Worth: ₹ 16.71 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Modern Diagnostic & Research Centre operates in Healthcare - Hospitals And Clinic and Provides Reliable Diagnostic Tests. The Issue is listed on BSE SME in Apr, 2025. Modern Diagnostic & Research Centre IPO size was with Issue price of .
Merchant Banker(s) of Modern Diagnostic & Research Centre IPO: Beeline Capital Advisors Private Limited
Modern Diagnostic & Research Centre IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Modern Diagnostic & Research Centre IPO listed at a listing price of against the offer price of .
The current market price of Modern Diagnostic & Research Centre is .
Why Us?
